Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Intratus over its Eyelid drug delivery platform. San Clemente, Calif.-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive Eyelid drug delivery platform for treating presbyopia, according to a news release. Financial terms were not disclosed. […]
Cure Pharmaceutical touts data from Curefilm Blue trial for erectile dysfunction
Cure Pharmaceutical announced today that it observed positive results from a trial for its Curefilm Blue platform. Oxnard, Calif.-based Cure touted the results of its initial pharmacokinetics (PK)/bioequivalence studies ahead of the advancement of its clinical program in pursuit of FDA approval, according to a news release. The company did not reveal the specific data, […]
Fresenius Kabi launches sodium chloride injection in Freeflex IV bags
Fresenius Kabi announced today that it launched two new presentations of Heparin sodium in its Freeflex IV bags. Lake Zurich, Ill.–based Fresenius Kabi’s Heparin sodium in sodium chloride injection at a concentration of two USP units per ml is indicated as an anticoagulant to maintain catheter patency, according to a news release. Available in two […]
Medtronic touts 2-year study results for In.Pact AV drug-coated balloon
Medtronic (NYSE:MDT) today touted safety and effectiveness results from a 24-month study of its In.Pact AV drug-coated balloon. Fridley, Minn.-based Medtronic said in a news release that the data demonstrated that the In.Pact AV DCB is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal […]
Code Biotherapeutics launches with $10M seed financing
Gene therapy developer Code Biotherapeutics announced today that it launched with $10 million in seed financing. Hatfield, Pa.-based Code Biotherapeutics develops 3DNA, a proprietary synthetic DNA-based vector designed to deliver genes of all sizes to multiple cell types as a re-dosable therapy, according to a news release. The company said it is focused on developing […]
Elektrofi, Argenx enter collaboration for subcutaneous product formulations
Elektrofi announced today that it is collaborating with Argenx to explore new subcutaneous formulations for therapeutics. Included in the collaboration are formulations for therapeutics directed at the human neonatal Fc receptor (FcRn), including efgartigimod and up to one additional target, according to a news release. The formulations are designed to promote additional optionality for patients […]
D&D Pharmatech to collaborate with Yale on brain cancer therapies
D&D Pharmatec announced today that it is collaborating with Yale to optimize two approaches to treating brain cancer and other disorders. The sponsored research agreement is slated to work with two novel approaches that allow immune system cells and drug molecules to bypass the blood-brain barrier (BBB) when treating brain cancer, among other diseases, according […]
Once-a-week insulin dosing shows promise in studies
Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes. Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according […]
Lyndra Therapeutics touts Phase 2 data for oral schizophrenia treatment
Lyndra Therapeutics yesterday announced positive results from a Phase 2 study of its once-weekly, oral schizophrenia treatment. Watertown, Mass.-based Lyndra’s oral, long-acting, extended-release risperidone capsule, LYN-005, is designed for the weekly treatment of schizophrenia. Data from the company’s first repeat-dose Phase 2 study demonstrate that LYN-005 offered sustained therapeutic levels of risperidone over the one-week […]
Pump problem prompts another Alaris recall
Days after classifying one recall for the Alaris infusion pump, the FDA has issued another Class I recall for the device. On Friday of last week, the FDA issued a Class I recall — the most serious kind — for the BD (NYSE:BDX) Alaris because there is a risk of the keypad lifting up due to […]
